Sequential Therapy Versus Quadruple Therapy in H. Pylori Eradication

Summary

The investigators aimed to 1. compare the eradication rates and long term re-infection rates of sequential therapy for 14 days versus bismuth quadruple therapy for 10 days in the first line and second line treatment 2. assess the impact of antibiotic resistance and CYP2C19 polymorphism on the eradication rate of these regimens 3. assess the impact of these eradication regimens on the antibiotic resistance and microbiota of the gut flora 4. assess the impact of eradication therapy on the metabolic factors

Timeline

Start

2015-09

Primary completion

2018-12

Completion

2019-12

Publications

• Liou JM, Chen CC, Fang YJ, Chen PY, Chang CY, Chou CK, Chen MJ, Tseng CH, Lee JY, Yang TH, Chiu MC, Yu JJ, Kuo CC, Luo JC, Hsu WF, Hu WH, Tsai MH, Lin JT, Shun CT, Twu G, Lee YC, Bair MJ, Wu MS; Members of the Taiwan Gastrointestinal Disease and Helicobacter Consortium. 14 day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: a multicentre, non-inferiority, randomized trial. J Antimicrob Chemother. 2018 Sep 1;73(9):2510-2518. doi: 10.1093/jac/dky183.

Drugs

Indications